EASD – Presentation by Yvo op den Kamp

Last week during the virtual EASD meeting, Yvo op den Kamp presented his work on the effects of 5 weeks of treatment with dapagliflozin, a SGLT2 inhibitor, on energy metabolism in patients with type 2 diabetes. The key messages of this presentation were that dapagliflozin treatment vs placebo resulted in:

  • Unchanged 24-h energy expenditure, while 24-h fatty acid oxidation increased, inducing a negative fat balance
  • Improved metabolic flexibility as indicated from a larger difference in day- versus night-time RER
  • Unchanged skeletal muscle insulin sensitivity, while adipose and hepatic insulin sensitivity improved
  • Lower intrahepatic lipid content